

15 September 2025

**CVS Group plc**

("CVS" or the "Company")

**PDMR Shareholding Correction**

CVS, the UK's listed veterinary group and a leading provider of veterinary services, issues a correction to the announcement dated 25 July 2024 regarding the shares held by Paul Higgs, Director and Chief Veterinary Officer of the Company.

The Company confirms that Paul Higgs' holding in the Company is 3,696 ordinary shares of 0.2p each ("Ordinary Shares") not 6,364 as stated in the above announcement. This includes all persons closely associated.

The holding of 3,696 Ordinary Shares represents 0.005% per cent of the total voting rights of the Company.

Contacts:

CVS Group plc

via Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

Peel Hunt LLP (Nominated Adviser & Joint Broker)  
Christopher Golden / James Steel / Andrew Clark

+44 (0)20 7418 8900

Berenberg (Joint Broker)  
Toby Flaux / Michael Burke / Milo Bonser

+44 (0)20 3207 7800

Camarco (Financial PR)

Ginny Pulbrook

+44 (0)7961 315 138

Letaba Rimell

Tilly Butcher

About CVS Group plc ([www.cvsukltd.co.uk](http://www.cvsukltd.co.uk))

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCPKPBQPBKDQCD